Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer

Applicable to Parts 1 and 2

1. Have metastatic disease, defined by ≥ 1 metastatic lesion that is present on baseline computed tomography (CT), magnetic resonance imaging (MRI), or bone scan imaging

2. Have documented progressive mCRPC based on ≥ 1 of the criteria (per PCWG3)

3. Have been treated with ≥ 1 second-generation androgen-signaling inhibitor, including abiraterone, apalutamide, darolutamide, and/or enzalutamide

4. Have been treated with ≥ 1 prior taxane regimens (e.g., docetaxel, cabazitaxel)

5. Are deemed unsuitable for standard of care

Applicable to Part 2, 3a and Part 4a,

1. Have metastatic CRPC, defined by ≥ 1 metastatic lesion that is present on baseline CT, MRI, or bone scan imaging that has documented progressive disease (PD) based on ≥ 1 of the following criteria (per PCWG3):

2. Participants with metastatic hormone sensitive prostate cancer (mHSPC) or with biochemical recurrent prostate cancer (BRPC) may also participate in select cohorts of this clinical trial.

1. Presence of dominant histopathological features representative of sarcomatoid, spindle cell, or neuroendocrine small cell components

2. Has acute or chronic infections

3. Has a concomitant medical or inflammatory condition that may increase the risk of toxicity to VIR-5500 (AMX-500), per the Investigator

4. Has lesions in proximity of vital organs

5. Has known active CNS metastases and/or carcinomatous meningitis The above information is not intended to contain all considerations relevant to a patient’s potential participation in a clinical trial.